Eric M. Verdin
Eric M. Verdin is a geroscientist, researcher, and professor who has served as President and chief executive officer of the Buck Institute for Research on Aging since 2016.[1][2][3]
Life and Career
Eric M. Verdin was born in Belgium[4]. He has a BS in Medical Sciences and doctorate of medicine from the University of Liege.[4]
After graduating from university, Verdin trained at Harvard Medical School.[5] In 1997, he joined the Gladstone Institute for Virology and Immunology, where he worked for twenty years.[5][4]
He is also a professor of medicine at the University of California, San Francisco.[6]
Selected publications
Verdin has an h-index of 103[7] and has published more than 210 scientific papers including:[5]
- Verdin, Eric (2015-12-04). "NAD+ in aging, metabolism, and neurodegeneration". Science. 350 (6265): 1208–1213. Bibcode:2015Sci...350.1208V. doi:10.1126/science.aac4854. ISSN 0036-8075. PMID 26785480. S2CID 27313960.
- Verdin, Eric; Ott, Melanie (2015). "50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond". Nature Reviews Molecular Cell Biology. 16 (4): 258–264. doi:10.1038/nrm3931. ISSN 1471-0080. PMID 25549891. S2CID 10192177.
- Gut, Philipp; Verdin, Eric (2013-10-24). "The nexus of chromatin regulation and intermediary metabolism". Nature. 502 (7472): 489–498. Bibcode:2013Natur.502..489G. doi:10.1038/nature12752. ISSN 1476-4687. PMID 24153302. S2CID 4471359.
- Shimazu, Tadahiro; Hirschey, Matthew D.; Newman, John; He, Wenjuan; Shirakawa, Kotaro; Le Moan, Natacha; Grueter, Carrie A.; Lim, Hyungwook; Saunders, Laura R. (2013-01-11). "Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor". Science. 339 (6116): 211–214. Bibcode:2013Sci...339..211S. doi:10.1126/science.1227166. ISSN 0036-8075. PMC 3735349. PMID 23223453.
- Hirschey, Matthew D.; Shimazu, Tadahiro; Jing, Enxuan; Grueter, Carrie A.; Collins, Amy M.; Aouizerat, Bradley; Stančáková, Alena; Goetzman, Eric; Lam, Maggie M. (2011-10-21). "SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome". Molecular Cell. 44 (2): 177–190. doi:10.1016/j.molcel.2011.07.019. ISSN 1097-4164. PMC 3563434. PMID 21856199.
- Hirschey, Matthew D.; Shimazu, Tadahiro; Goetzman, Eric; Jing, Enxuan; Schwer, Bjoern; Lombard, David B.; Grueter, Carrie A.; Harris, Charles; Biddinger, Sudha (2010-03-04). "SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation". Nature. 464 (7285): 121–125. Bibcode:2010Natur.464..121H. doi:10.1038/nature08778. ISSN 1476-4687. PMC 2841477. PMID 20203611.
References
- "CEO Eric Verdin Buck Institute". www.bizjournals.com. Retrieved 2023-05-11.
- "The Buck Institute, Where the Promise of Aging Research Isn't Longevity". proto.life. 2022-07-28. Retrieved 2023-05-11.
- "Buck Institute for Research on Aging names new CEO, announces $10M board donation". Retrieved 2017-03-06.
- "CEO Eric Verdin talks Buck Institute's new push to collaborate with pharma". www.bizjournals.com. Retrieved 2023-05-11.
- "Novato's Buck gets $10M gift, names new CEO". The North Bay Business Journal. 2016-11-25. Retrieved 2023-05-16.
- "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing". Nature. 583 (7816): 459–468. July 2020. doi:10.1038/s41586-020-2286-9. ISSN 1476-4687.
- "Eric Verdin – Google Scholar Citations". scholar.google.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.